Feasibility and acceptability of persons on long-acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study.

ABSTRACT:

Introduction

Injectable cabotegravir (CAB-LA) is highly effective for HIV prevention, but real-world implementation studies in Africa are ongoing. We assessed feasibility and acceptability among participants who used CAB-LA in the SEARCH Dynamic Choice HIV Prevention extension study in rural Uganda and Kenya.

Methods

From January 2023 to December 2024, we followed females and males who were aged ≥ 15 years, with self-assessed risk for HIV acquisition, in the intervention arm of the SEARCH Dynamic Choice HIV Prevention extension study, and received at least one CAB-LA injection during the first 48 weeks. To assess the feasibility and acceptability of CAB-LA, we designed quantitative surveys based on the Theoretical Framework for Acceptability. Surveys were administered at CAB

SUBMITTER: Kakande ER 

PROVIDER: S-EPMC12215826 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature